Sage Journals: Discover world-class research

Abstract

Cardiac surgery in Jehovah’s Witness patients remains a challenge in the presence of concomitant congenital or acquired coagulation disorders and anaemia. We report a case of a 66-year-old female Jehovah’s Witness suffering from severe calcified aortic valve stenosis requiring aortic valve replacement. The anaemic patient suffered from concomitant platelet dysfunction and deficiency of factors V and VII due to gammopathy of immunoglobulin G. The patient was preoperatively treated with recombinant erythropoietin in combination with folic acid and iron, which resulted in an increase of the haematocrit from 0.335 to 0.416 after 22 days of treatment. Haemostasis was improved by high dose aprotinin and additional desmopressin, which could be demonstrated to be effective by a preoperative test. The patients intra- and postoperative course was uneventful, her total chest tube loss was 130 ml, and she was able to be discharged without the need of any blood transfusions. The beneficial properties of erythropoietin and desmopressin in Jehovah’s Witness patients are discussed.

Get full access to this article

View all access options for this article.

References

Bidstrup BP , Royston D , Sapsford RL , Taylor KM. Reduction of blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) . J Thorac Cardiovasc Surg 1989; 97: 364-372 .

Manucci PM. Hemostatic drugs . N Engl J Med 1998; 339: 245-253 .

Fremes SE , Wong BI , Lee E et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding . Ann Thorac Surg 1994; 58: 1580-1588 .

Rosengart TK , Helm RE , DeBois WJ et al. Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah’s Witness patients: implications for a ‘bloodless’ surgical techique . J Am Coll Surg 1997; 184: 618-629 .

Royston D , Bidstrup BP , Taylor KM , Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open heart surgery . Lancet 1987; 2: 1289-1291 .

Dietrich W , Spannagl M , Jochum M et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularisation . Anesthesiology 1990; 73: 1119-1126 .

De Smet AA , Joen MC , van Oeveren W et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin . J Thorac Cardiovasc Surg 1990; 100: 520-527 .

Cosgrove DM III , Heric B , Lytle BW et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study . Ann Thorac Surg 1992; 54: 1031-1038 .

Eschbach JW , Egric JC , Downing MR , Browne JK , Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin . N Engl J Med 1987; 316: 73-78 .

10.

Adamson JW. Iron and erythropoiesis. In: Bauer C , Koch KM , Scigalla P , Wieczorek L eds. Erythropoietin - molecular physiology and clinical applications. New York: Marcel Dekker , 1993: 161-176.

11.

Goodnough LT , Price TH , Rudnick S. Iron-restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow . J Lab Clin Med 1991; 118: 289-296 .

12.

Rutherford CJ , Schneider TJ , Dempsey H , Kirn DH , Brugnara C , Goldberg MA. Efficacy of different dosing regimes for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response . Am J Med 1994; 96: 139-145 .

13.

Konertz W. Use of desmopressin in open heart surgery . Res Clin For 1997; 19: 21-24 .

14.

Jovanovic S , Hansbro SD , Munsch CM , Cross MH. Redo cardiac surgery in a Jehovah’s Witness, the importance of a multidisciplinary approach to blood conservation . Perfusion 2000; 15: 251-255 .

15.

Gaudiani VA , Mason DW. Preoperative erythropoietin in Jehovah’s Witnesses who require cardiac procedures . Ann Thorac Surg 1991; 51: 823-824 .

16.

Lethagen S. Desmopressin - a haemostatic drug: state-of-the-art review . Eur J Anaesthesiol 1997; 14 (Suppl.): 1-9 .

17.

Lethagen S. General use of desmopressin: the coagulationist’s view . Res Clin For 1997; 19: 7-18 .

18.

Stel HV , van der Kwast TH , Veerman ECI. Detection of factor VIII/coagulant antigen in human liver-tissue . Nature 1983; 303: 530-532 .

19.

Cash JD , Gader AMA , Da Costa J. The release of plasminogen activator VIII by LVP, AVP, DDAVP, ATIII and OT in man . Br J Haematol 1974; 27: 363-364 .

20.

Nachman RL , Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor . J Exp Med 1975; 141: 1101-1113 .

21.

Salzman EW , Weinstein MJ , Weintraub RM et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomised trial . N Engl J Med 1986; 314: 1402-1406 .

22.

Mongan PD , Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification . Anesthesiology 1992; 77: 38-46 .

23.

Lethagen S. Suggested treatment guidelines for desmopressin use in general and cardiac surgery . Res Clin For 1997; 19: 57-60 .

Use of desmopressin and erythropoietin in an anaemic Jehovah’s Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement

Abstract

Get full access to this article

References